RxDoctor Payments Data

Kira Bleecher, MD

Psychiatry · Glen Allen, VANPI 1164868469

Payments from drug & device makers

$930in general payments, 2019–2025

Across 48 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$206
  • Indivior Inc.$183
  • Johnson & Johnson$115
  • AbbVie$101
  • Braeburn Inc.$98
  • Alkermes, Inc.$95
  • plus $131 from 6 others

What the payments were for

  • Food & beverage$91799%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$930 in reported general payments places this provider in the 70th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$33,576
Medicare patients
63
Services billed
515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$93,190
VraylarCariprazine Hcl14$20,794
SuboxoneBuprenorphine Hcl/Naloxone Hcl23$14,262
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl56$8,360
Gabapentin52$932
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine29$877
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine21$716
Quetiapine Fumarate30$573
Bupropion XlBupropion Hcl33$542
Clonazepam39$466
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$420
Olanzapine19$410
Baclofen27$394
Duloxetine Hcl37$393
Mirtazapine19$343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$18$93,19012 claims
AbbVieVraylar$101$20,79414 claims
Indivior Inc.Suboxone$183$14,26223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Glen Allen

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →